Position:
Associate Professor
Division:
Respiratory
Education:
MD Queen’s University
Recent Publications:
  • Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, Berthiaume Y, Brown N, Wilcox P, Bye P, Bell S, Noseworthy M, Pedder L, Freitag A, Paterson N, Aaron SD. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 61:969-74. 2006.
  • Al Lawati NM, Wilcox P.  Paradoxical embolization in an adult cystic fibrosis patient. Can Respir J. 14:293-294, 2007.
  • APTalag A, Wilcox P. Clinical physiology of COPD. BCMJ. 50 97 – 102,  2008.
  • Blohmke C, Victor R, Hirscheld A, Elias I, Hancock D, Lane C, Davidson G, Wilcox P, Smith K , Hancock R, Turvey S   Innate Immunity Mediated by TLR5 as a Novel Antiinflammatory Target for Cystic Fibrosis Lung Disease.  Journal of Immunology 180 7764-73, 2008.
  • Miller R, Tildesley H, Wilcox P, Zhang H, Kreisman S. Gender disparities in effects of cystic fibrosis related diabetes on clinical outcomes: a matched study.  Journal of Cystic Fibrosis. 7 S85 2008.
  • Ryerson C, Churg A, Wilcox P.  Pleural Effusion: A Diagnostic Dilemma. Chest. 136(3): 934-7, 2009.
  • Vandemheen K, O’Connor A, Bell S, Freitag A, Bye P, Jeanneret A, Bertiaumme Y, Brown N, Wilcox P, Ryan G, Rabin H, Morrisson N, Paterson N, Aaron S.  Randomized Trial of a Decision Aid for Cystic Fibrosis Patients considering Lung Transplantation  Am J Resp Crit Care Med. 180: 761-8, 2009.
  • Wilcox P. Interstitial Lung Disease in Systemic Sclerosis  Canadian Respiratory Journal. 17: 42, 2009.
  • Tseng O, Wilcox P, Kelsall. Pulmonary Infiltrates with Eosinophilia associated with Piperacillin/Tazobactam accepted  Canadian Respiratory Journal 2010.
  • Dunne J, Chou JP, Viswanathan M, Wilcox P, Huang S. Cardiac Tamponade and Large Pericardial Effusions in Systemic Sclerosis. Clin Rheumatology 30 433-8 2011.
  • Pandey AK, Wilcox P, Mayo JR, Moss R, Ellis J, Brown J, Kavishwar A, Leipsic J. Oesophageal Dilatation on High Resolution CT Chest in Systemic Sclerosis – What does it Signify? J Med Imaging and Rad Oncol 55 551-5 2011.
  • Quon BS, Reid P, Wong P, Wilcox PG, Javer A, Wilson JM, Levy RD. Burkholderia Gladioli – A predictor of poor outcome in Cystic Fibrosis patients who receive Lung Transplants. Can Respir J 2011 18 e64-65.
  • Zlosnik JEA, Costa PS, Brant R, Mori PYB, Hird TJ, Fraenkel MC, Wilcox PG, George A. Davidson F, Speert DP. Mucoid and Nonmucoid Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Infections. Am. J. Respir. Crit. Care Med. 2011; 183: 67-72.
  • Aaron SD, Vandemheen K, Freitag A, Pedder L, Cameron W, Lavoie A, Paterson N, Wilcox P, Rabin H, Tullis E, Morrison N, Ratjen F. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: A randomized, placebo-controlled pilot study. Accepted for Publication PLoS ONE 2012.
  • Ngan D, Wilcox P, Aldaabil M, Li Y, Leipsic J, Sin D, Man P. The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis. BMC Pulmonary Medicine accepted for publication 2012.